

The questions below were submitted by shareholders to the company's website as requested in the Notice of Annual General Meeting, issued on 17<sup>th</sup> June 2021.

Q: 1. Any progress with Actial and the launch of VSL cardio? Is there a launch date ?

A1 Actial are progressing with the registration and launch of a VSL#3 Cardio range in Australia, New Zealand, Indonesia, Thailand, France and Malaysia through their distributor network. Progress varies across each territory and Actial are cautious about publicly releasing launch dates. We will update the market on the first product launch.

Q2: Do you still anticipate the sweetbiotix deals to be announced in 2021? How is the manufacturing ramp up progressing?

A2: There has been good progress of the Company's manufacturing partner scaling up SweetBiotix® as an ingredient. Industrial scale up is using new manufacturing processes which have had to be developed by our partner with our support. This ingredient will be shared with application partners as the final production product and subjected to taste, stability, structural and functional analysis tests to make sure it has the same characteristics as the earlier laboratory scale products. We are paralleling this work with the release of a number of independent peer reviewed publications demonstrating prebiotic activity and superior taste profile.

The company has a number of Material Transfer agreements, Heads of Terms, and Open Innovation arrangements already in place with global partners and would hope a number of these translate into formal commercial agreements. In the interim our manufacturing partner is paying us six figure annual payments to ensure they remain focused on scale up.

Q3: General progress and chances of getting another 100% plus sales growth?

A3: This year looks like another good year with record sales and reducing costs with larger orders as our partners extend their product lines and take products into new territories. As I constantly remind investors orders vary from month to month and a single large order can have a disproportionate effect on monthly or even half yearly numbers. Despite this caveat I am really pleased with the sales growth and progress of the company at this stage of its commercial development. It is extremely pleasing to see large partners extending their product range and territories in which they want to sell our products.

Q4: There is very limited information available on either Sweetbiotix or the Microbiome Modulators. Can more information not be provided or is it all subject to nda's or ongoing commercial discussions.

A4: The company updated progress on its SweetBiotix products in March 2021 and more recently in its annual report published in June. I have also commented on progress above in response to Q2. There are also two publications on SweetBiotix and a further publication under way.

On reviewing our website I note the absence of information on both these products so will look to update.

Q5 Is the registration process underway for any lpldl/slimbiome/wellbiome products for the Chinese market currently in progress? And how long would such a process likely take?

I have carried out a lot of business in China in the past. It's a large and complex market where patent protection provides less security than other countries and regulatory processes vary depending on whether the product is sold on line or in stores and in what format (tablets, capsules, sachets). To overcome these challenges companies tend to enter the Chinese market once they have built a brand, as this gives Chinese customers a level of confidence in the provenance of the product. Our strategy is to first build a brand presence in Western markets which we have largely achieved. The next part of the strategy is to increase awareness and brand reputation in a number of geographies in Asia. This is key to entering China where IP has less value and brands give differentiation from copycat products. It also allows us to enter China using cross border ecommerce sales where regulatory barriers are often lower so we can assess market acceptance and adjust (e.g flavours, pack sizes) accordingly. We are taking a multi-tiered approach to entering the Asian market and hope to update shareholders on potential developments in the months ahead.